Available trials in the United States: Trial Insights

Filters: Status: Available Country / region: United States Clear all

85 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2014	1

Trials by status
Category	Trials
Available	85

Top lead sponsors
Category	Trials
Children's Hospital of Philadelphia	2
Cogent Biosciences, Inc.	2
Genentech, Inc.	2
Hope Biosciences Research Foundation	2
ImmunityBio, Inc.	2
Joanne Kurtzberg, MD	2
Kite, A Gilead Company	2
Matrix Biomed, Inc.	2
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany	2
Takeda	2

Top conditions
Category	Trials
Neoplasms	6
Carcinoma, Non-Small-Cell Lung	5
Neuroblastoma	5
Glioblastoma	4
Precursor Cell Lymphoblastic Leukemia-Lymphoma	4
Epilepsy	3
Hypoglycemia	3
Prostatic Neoplasms	3
Amyotrophic Lateral Sclerosis	2
Breast Neoplasms	2

Trials

Showing 26 to 50 of 85. Each trial links to its page on Pharma Observatory.

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis NCT04474990Expanded accessAvailableVanda Pharmaceuticals
Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI NCT04513821Expanded accessAvailableLeonard-Meron Biosciences, Inc.
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies NCT04566393Expanded accessAvailablexCures
Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma NCT04571229Expanded accessAvailableMemorial Sloan Kettering Cancer Center
Compassionate Use of Concizumab if You Have Haemophilia NCT04921956Expanded accessAvailableNovo Nordisk A/S
Individual Patient Compassionate Use of Mirdametinib NCT05028166Expanded accessAvailableSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Individual Patient Compassionate Use of Nirogacestat NCT05041036Expanded accessAvailableSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009 NCT05134922Expanded accessAvailableCelcuity Inc
Expanded Access for Apixaban NCT05187286Expanded accessAvailableBristol-Myers Squibb
Three Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01, CNMAu8.EAP02, and CNMAu8.EAP06 for ALS NCT05281484Expanded accessAvailableClene Nanomedicine
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma NCT05346835Expanded accessAvailableJanssen Scientific Affairs, LLC
Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release NCT05398640Expanded accessAvailableIovance Biotherapeutics, Inc.
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children NCT05424731Expanded accessAvailableDBV Technologies
Treatment of Metastatic Cancer in Terminally Diagnosed Patients NCT05491928Expanded accessAvailableMatrix Biomed, Inc.
Expanded Access [11C] Methionine PET Imaging NCT05511714Expanded accessAvailableSt. Jude Children's Research Hospital
NTX-001 to Repair Peripheral Nerve Transection(s) NCT05565846Expanded accessAvailableNeuraptive Therapeutics Inc.
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884) NCT05572970Expanded accessAvailableAgenus Inc.
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel NCT05776134Expanded accessAvailableKite, A Gilead Company
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel NCT05776160Expanded accessAvailableKite, A Gilead Company
NRX-101 Expanded Access NCT05779267Expanded accessAvailableNeuroRx, Inc.
Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome NCT05795361Expanded accessAvailableTakeda
Early Access Program for Zolbetuximab NCT06048081Expanded accessAvailableAstellas Pharma Global Development, Inc.
Intermediate-Size Expanded Access Protocol (EAP) for LP352 NCT06149663Expanded accessAvailableLongboard Pharmaceuticals
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors NCT06370013Expanded accessAvailableTransThera Sciences (Nanjing), Inc.
Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use) NCT06393660Expanded accessAvailableVictor Aquino

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory